Lapuroon Aurora Vivid PDRN 0.2%
Biotechnology-Driven Dermal Regenerator with 98.7% Purity Polynucleotide Complex
Advanced Polynucleotide Technology & Dermatological Grade Standard
Lapuroon Aurora Vivid utilizes patented PDRN extraction technology (EU Patent No. EP3287151B1) to process salmon DNA-derived polynucleotides under strict ISO 22716/GMP conditions. The formulation contains 0.2% medical-grade PDRN combined with 3% stabilized ascorbic acid and biomimetic peptides, achieving 92% free radical neutralization capacity. Clinical studies demonstrate 41% increase in fibroblast proliferation and 2.3× accelerated tissue repair compared to baseline treatments. Molecular analysis confirms 98.7% purity with complete removal of non-therapeutic nucleic acids.
Clinically Validated Benefits
Barrier Repair
27% increase in epidermal lipids and 32% reduction in TEWL (Transepidermal Water Loss)
Wrinkle Reduction
18% depth decrease in static wrinkles within 28 days (3D imaging analysis)
Pigmentation Control
35% reduction in melanin index (MI) by week 8 (Mexameter® measurements)
Dermal Restructuring
15% increase in dermal thickness confirmed via histological analysis
Pharmaceutical Specifications
- Active Substance: Polynucleotide (PDRN) 0.2% + 3% Ascorbic Acid
- Packaging: Pre-filled syringe 2.5ml
- Production Standard: ISO 22716/GMP Certified
- Sterility: 0.22μm filtration, 99.99% microbial exclusion
- Storage: 15-25°C in original packaging
- Shelf Life: 24 months from manufacture date
Clinical Protocol
- Dosage: 0.1-0.2ml per injection point
- Administration: Intradermal using 30G needle
- Treatment Course: Every 4 weeks for optimal results
- Maximum per Session: 2.0ml total volume
- Needle: 30G × 4mm (BD Ultra-Fine™ compatible)
Therapeutic Applications
Aging Skin
For static wrinkles: Administer 0.1ml per cm² at 4mm depth. Clinical data shows 18% improvement in wrinkle depth after 4 sessions spaced 28 days apart.
Hyperpigmentation
For melasma: Microinject 0.05ml per cm² with 5mm spacing. Combine with broad-spectrum SPF50+ for 78% faster resolution versus monotherapy.
Acne Scarring
For atrophic scars: 0.2ml per 2cm² area with cross-hatching technique. Demonstrated 2.1× faster collagen remodeling in RCTs.
Important Clinical Notice
Notice: Therapeutic outcomes may vary based on individual biological factors and skin types. All treatments must be performed by licensed dermatologists or aesthetic physicians. Strict contraindications include: active skin infections, known hypersensitivity to marine-derived products, and pregnancy.
This product is not a substitute for medical treatment of underlying conditions. Post-treatment erythema typically resolves within 24-48 hours. Discontinue immediately if persistent irritation or allergic reactions occur.
Reviews
There are no reviews yet.